What is the reported incidence of hair thinning on tirzepatide in STEP 3?

The case in front of me: hair thinning · tirzepatide · STEP 3.

I would like to know the limits of what can be inferred from this.

What I am trying to avoid is over-reading a single result, which I have done before.

How should I read this, and where are the traps?

The incidence figures are dose-related but the timing is escalation-related, and conflating the two produces most of the bad advice in this area. Adverse events cluster in the one to two weeks following each dose increase, then decay.

Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.

The part that matters: injection-site reactions are more often diluent-related than peptide-related. Benzyl alcohol sensitivity is uncommon but real, and it presents as a consistent local reaction at every site with a preserved diluent and no reaction with an unpreserved one — which is a straightforward thing to establish. Injection depth is the other common cause: intradermal placement stings and welts, subcutaneous placement usually does not.

The prescribing information for each agent lists adverse reaction frequencies against placebo in a table, and reading that table is more informative than reading a hundred anecdotes, because it has a denominator.

The limitation of the timing heuristic is that it works well for common events and poorly for rare ones, which are precisely the ones that matter most.

Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.

Timing is the most useful diagnostic feature here and it is the one most often omitted from the question.

The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.

Vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.

SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].

Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.

The honest framing is that this is very common, usually self-limiting, and occasionally the presentation of something that is not self-limiting at all — and the differentiating features are specific enough to be worth knowing.

Distinguishing an injection-site nodule from an infection: a nodule is firm, non-tender or mildly tender, not warm, not expanding, and appears within a day or two. Cellulitis is warm, tender, expanding, and often accompanied by systemic features. A sterile abscess sits between the two and is fluctuant. Warmth plus expansion plus fever is the combination that stops being a forum question.

Pooled analyses of gallbladder-related events with GLP-1 receptor agonists find a modest increase in relative risk, with the effect larger at higher doses and longer durations — consistent with a rate-of-loss mechanism as much as a direct one[1].

If the timing does not fit the escalation, look for another explanation before settling on the drug.

To be exact about it, the distinction worth making early is between a tolerability problem, which is unpleasant and self-limiting, and a clinical problem, which is neither. They present differently and the thresholds for each are worth writing down before you need them.

Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.

Worth being explicit: nothing here is medical advice, and research-use-only compounds are not approved for human use.

A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.